KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Astrana Health (ASTH) over the last 15 years, with Q3 2025 value amounting to $2.6 million.

  • Astrana Health's Capital Expenditures rose 1119.83% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 7229.51%. This contributed to the annual value of $8.0 million for FY2024, which is 7184.97% down from last year.
  • As of Q3 2025, Astrana Health's Capital Expenditures stood at $2.6 million, which was up 1119.83% from $1.4 million recorded in Q2 2025.
  • Astrana Health's 5-year Capital Expenditures high stood at $17.5 million for Q1 2022, and its period low was $98000.0 during Q1 2021.
  • Over the past 5 years, Astrana Health's median Capital Expenditures value was $2.8 million (recorded in 2024), while the average stood at $4.5 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 1774591.84% in 2022, then crashed by 9387.76% in 2024.
  • Astrana Health's Capital Expenditures (Quarter) stood at $2.8 million in 2021, then plummeted by 68.39% to $886000.0 in 2022, then surged by 696.5% to $7.1 million in 2023, then plummeted by 64.13% to $2.5 million in 2024, then increased by 0.83% to $2.6 million in 2025.
  • Its Capital Expenditures stands at $2.6 million for Q3 2025, versus $1.4 million for Q2 2025 and $3.1 million for Q1 2025.